|
Cambridge Discovery Chemistry, formerly Cambridge Combinatorial, a
wholly owned subsidiary of Oxford Molecular Group plc, and Zeneca
Agrochemicals, the crop protection and plant science business of
AstraZeneca, today (13th December) announced a major chemistry
R&D collaboration. Cambridge Discovery Chemistry will take over responsibility for Zeneca’s
chemistry research facility within Zeneca’s R & D Centre in
Richmond, San Francisco, CA. The collaboration strengthens Cambridge
Discovery Chemistry’s business in North America and makes the company
one of the first in its field to have research facilities in both the US
and Europe. Research carried out by Cambridge Discovery Chemistry will be funded,
for a defined period, by Zeneca Agrochemicals, providing flexibility in
managing the level of resource required in its discovery programmes. The
agreement initially involves Cambridge Discovery Chemistry providing
chemistry services to Zeneca, with the potential to increase the number of
participating research scientists. Additionally, Cambridge Discovery Chemistry will be able to expand the
facilities to accommodate ongoing growth requirements, and new discovery
programmes from its pharmaceutical, agrochemical and biotechnology
business. Dr Allan Marchington, Chief Executive of Cambridge Discovery Chemistry,
said: "This agreement will allow us to expand our chemistry capacity
and establish a high-quality, research base in the US. We will build a
strong medicinal chemistry function in San Francisco to complement the
existing chemists’ capabilities in combinatorial chemistry and
automation." Zeneca Agrochemicals’ Director of Research and Development, Dr David
Evans, said: "This collaboration offers us the opportunity to combine
world-class combinatorial chemistry expertise in a flexible research
arrangement which will greatly benefit both our businesses."
For further information, please contact: Zeneca Agrochemicals: Ian Weatherhead,
External Relations Manager HCC·De Facto Group plc Cambridge Discovery Chemistry Cambridge Discovery Chemistry (formerly known as Cambridge Combinatorial Limited) provides world-class, innovative chemistry services to accelerate discovery and process research, servicing the pharmaceutical, agrochemical and biotechnology industries. The Company is a wholly owned subsidiary of Oxford Molecular Group Plc. Cambridge Discovery Chemistry has developed leading technologies for discovery research including innovative molecular design, novel chemistries, new synthetic chemistry platforms and a comprehensive integrated informatics system. The company acts as an extension to the resources of its collaborators with solutions for discovery research including medicinal and combinatorial chemistry for lead generation, validation, optimisation and technology transfer as required.Cambridge Discovery Chemistry supplies the molecular design and synthesis arm of Oxford Molecular’s Collaborative Discovery. Collaborative Discovery acts as a central point for multi-disciplinary research projects involving both chemistry and biology research. Cambridge Discovery Chemistry has secured many discovery collaborations with a range of pharmaceutical, agrochemical and biotechnology companies spanning the US, Japan and Europe these include: Merck & Co. Inc., Pfizer, Procter & Gamble Pharmaceuticals Inc., Rohm & Haas, Alizyme, Solvay Pharmaceuticals, Mitsubishi Chemical Corporation, Yamanouchi and Fujisawa.
Oxford Molecular Group plc Oxford Molecular is a leading provider of discovery and software solutions to the life sciences market. The Company seeks to deliver excellence in all its products and services and to help its customers benefit from the synergy that is created from the integration of state-of-the-art chemistry, biology and information technology infrastructure. The Discovery Solutions Division offers discovery research through collaboration, by providing world-class innovative technologies in chemistry and biology which intimately match customer needs and add value to their research programmes. The Software Solutions Division supplies enterprise-wide software and information technology solutions for research across the entire drug discovery process. Innovative and superior products target customer needs for excellence in each area of discovery research; and together they form integrated solutions that add value to the flow of information through the customer’s research process. The Company has its headquarters in Oxford, England and has operations throughout the USA as well as sales offices and agents around the world. |